ReviewFrontiers in pharmacology2014
Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major.
Review in Frontiers in pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Trial
- Combinatorial approach to treat iron overload cardiomyopathy in pediatric patients with thalassemia-major: A systematic review and meta-analysis.World journal of cardiology · 2025Article
- Correlation of Electrocardiographic and Echocardiographic Changes with Serum Ferritin Level in Multi-Transfused β-Thalassemia Major Patients.Indian journal of pediatrics · 2024Article
- CHMMOTv1 - cardiac and hepatic multi-echo (T2BMC research notes · 2023Article
- Ebselen: A promising therapy protecting cardiomyocytes from excess iron in iron-overloaded thalassemia patients.Open medicine (Warsaw, Poland) · 2023Review
- Cardiovascular Magnetic Resonance Parametric Mapping Techniques: Clinical Applications and Limitations.Current cardiology reports · 2021Review
- Effects of mine waste water on rat: bioaccumulation and histopathological evaluation.Environmental science and pollution research international · 2021Article
- Early detection of ventricular dysfunction by tissue Doppler echocardiography related to cardiac iron overload in patients with thalassemia.The international journal of cardiovascular imaging · 2021Article
- Review
- Direct measurements of ferric reductase activity of human 101F6 and its enhancement upon reconstitution into phospholipid bilayer nanodisc.Biochemistry and biophysics reports · 2020Article
- Influence of mitochondrial and systemic iron levels in heart failure pathology.Heart failure reviews · 2019Review
- Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience.La Radiologia medica · 2018Article
- Structural basis for promotion of duodenal iron absorption by enteric ferric reductase with ascorbate.Communications biology · 2018Article
- T2 mapping and T2* imaging in heart failure.Heart failure reviews · 2017Review
- Assessment of Heart and Liver Iron Overload in Thalassemia Major Patients Using T2* Magnetic Resonance Imaging.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2017Article
- Iron Homeostasis in Health and Disease.International journal of molecular sciences · 2016Review
- Heart Rate Variability for Early Detection of Cardiac Iron Deposition in Patients with Transfusion-Dependent Thalassemia.PloS one · 2016Article
- Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms.Oxidative medicine and cellular longevity · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In conditions requiring repeated blood transfusion or where iron metabolism is abnormal, heart failure may result from accumulation of iron in the heart (cardiac siderosis). Death due to heart failure from cardiac iron overload has accounted for considerable early mortality in β-thalassemia major. The ability to detect iron loading in the heart by cardiovascular magnetic resonance using T2* sequences has created an opportunity to intervene in the natural history of such conditions. However, effective and well tolerated therapy is required to remove iron from the heart. There are currently three approved commercially available iron chelators: deferoxamine, deferiprone and deferasirox. We review the high quality randomized controlled trials in this area for iron chelation therapy in the management of cardiac siderosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.